Aspen Pharmacare faced a turbulent 2025 marked by a severe earnings downgrade and shaken investor trust. In early 2025, Aspen announced that EBITDA for the financial year would be R2 billion below prior guidance. This surprise came just weeks after the company’s interim results, catching markets off guard and sending its share price plummeting by more than 30%. The earnings…